

0001598599-25-0000056-K Innate Pharma SA 2025012120250121060054060054060054 0 0001598599-25-000005 6-K  
2 20250121 20250121 20250121 Innate Pharma SA 0001598599 2836 0000000000 IO 1231 6-K 34 001-39084 25540232  
117 AVENUE DE LUMINY BP 30191 MARSEILLE IO 13009 33430303030 117 AVENUE DE LUMINY BP 30191  
MARSEILLE IO 13009 Innate Pharma, SA 20140129 6-K 1 a6k-iphx250121.htm 6-K DocumentUNITED  
STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-KREPORT OF FOREIGN  
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934Date of  
report: January 21, 2025Commission File Number: 001-39084Innate Pharma S.A.(Translation of registrant's name into  
English)Innate Pharma S.A.117 Avenue de Luminyâ€”BP 3019113009 Marseille, France+ 33 (0) 4 30 30 30(Address of  
principal executive office)Indicate by check mark whether the registrant files or will file annual reports under cover of  
Form 20-F or Form 40-F. Form 20-F [ X ]ÃÃÃ Form 40-F [ ]EXHIBIT INDEXExhibitÃÃÃ Description1.1Press  
Release dated January 21, 2025SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the  
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.INNATE  
PHARMA S.A.Date: January 21, 2025ÃÃÃ By:ÃÃÃ /s/ JONATHAN DICKINSONÃÃÃ Name:ÃÃÃ Jonathan  
DickinsonTitle:ÃÃÃ Chairman of the Executive Board and Chief Executive officer EX-99.1 2 exhibit991-250121.htm  
EX-99.1 DocumentEXHIBIT 99.1INNATE PHARMA ANNOUNCES NECTIN-4 ANTIBODY DRUG CONJUGATE  
INVESTOR AND ANALYST EVENT IN NEW YORKInnate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug  
Conjugate (ADC) program at clinical stageMarseille, France, January 21, 2025, 7:00 A.M. CETÃ Innate Pharma SA  
(Euronext Paris: IPH; Nasdaq: IPHA) (â€œInnateâ€” or the â€œCompanyâ€”) will host an event for institutional investors  
and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its lead  
antibody-drug candidate program, IPH4502. The event will be held in New York in a hybrid format on Wednesday,  
February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.â€”As we just updated our strategy with a focus on our  
ANKETÃ® platform and ADC programs, this meeting will be an opportunity to share the latest scientific and clinical  
advancements related to Nectin-4 and its potential in cancer treatment,â€” said Jonathan Dickinson, Chief Executive  
Officer of Innate PharmaEvent details:Date: February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT Registration: If you  
would like to attend the event, please register at this link: <https://form.jotform.com/250134241556348> For those who  
are unable to attend in person, a live webcast and replay will be on Innate Pharmaâ€”s website at: <https://www.innate-pharma.com>.About IPH4502IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely  
target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including urothelial  
carcinoma, where Nectin-4 expression is highest, breast cancer, non-small cell lung cancer and gastro-intestinal  
cancer.In non-clinical models, IPH45 is well tolerated and shows anti-tumor activity in vitro and in vivo. In September  
2024, the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate  
a Phase 1 clinical study of IPH4502.About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage biotechnology  
company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune  
system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKETÃ® (Antibody-based NK  
cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies  
(mAbs).Innateâ€”s portfolio includes several ANKETÃ® drug candidates to address multiple tumor types as well as  
IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in  
advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is  
developed with AstraZeneca in non-small cell lung cancer.Innate Pharma is a trusted partner to biopharmaceutical  
companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research  
and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD,  
Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com)  
and follow us on LinkedIn and X.Information about Innate Pharma shares:ISIN codeÃ :  
FR0010331421Ticker codeÃ : Euronext: IPH Nasdaq: IPHALEIÃ : 9695002Y8420ZB8HJE29Disclaimer on forward-  
looking information and risk factors: This press release contains certain forward-looking statements, including those  
within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use  
of certain words, including â€œanticipate,â€” â€œbelieve,â€” â€œcan,â€” â€œcould,â€” â€œestimate,â€” â€œexpect,â€”  
â€œmay,â€” â€œmight,â€” â€œpotential,â€” â€œexpectâ€” â€œshould,â€” â€œwill,â€” or the negative of these and similar  
expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are  
based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties,  
which could cause actual results to differ materially from those anticipated. These risks and uncertainties include,  
among other things, the uncertainties inherent in research and development, including related to safety, progression of  
and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory  
authorities of its product candidates, the Companyâ€”s reliance on third parties to manufacture its product candidates,  
the Companyâ€”s commercialization efforts and the Companyâ€”s continued ability to raise capital to fund its  
development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results,  
financial condition, performance or achievements to differ from those contained in the forward-looking statements,  
please refer to the Risk Factors (â€œFacteurs de Risque") section of the Universal Registration Document filed with the  
French Financial Markets Authority (â€œAMFâ€”), which is available on the AMF website <http://www.amf-france.org> or  
on Innate Pharmaâ€”s website, and public filings and reports filed with the U.S. Securities and Exchange Commission  
(â€œSECâ€”), including the Companyâ€”s Annual Report on Form 20-F for the year ended December 31, 2023, and  
subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the  
Companyâ€”s website and the AMF website are included for information only and the content contained therein, or  
that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press  
release.In light of the significant uncertainties in these forward-looking statements, you should not regard these  
statements as a representation or warranty by the Company or any other person that the Company will achieve its  
objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any  
forward-looking statements, whether as a result of new information, future events or otherwise, except as required by  
law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer  
to buy or subscribe to shares in Innate Pharma in any country.For additional information, please  
contact:ÃÃÃ InvestorsÃÃÃ Innate Pharma ÃÃÃ Henry Wheeler ÃÃÃ Tel.: +33 (0)4 84 90 32  
88ÃÃÃ Henry.Wheeler@innate-pharma.frÃÃÃ Media RelationsNewCapArthur RouilleTel. : +33 (0)1 44 71 00  
15innate@newcap.eu